Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02142218
NCT02142218
No Longer Available
Not Applicable

Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)

Bristol-Myers Squibb21 sites in 2 countriesJune 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsStage III (Unresectable) or Stage IV Advanced Melanoma
DrugsNivolumab

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stage III (Unresectable) or Stage IV Advanced Melanoma
Sponsor
Bristol-Myers Squibb
Locations
21
Status
No Longer Available
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.

Registry
clinicaltrials.gov
Start Date
June 2014
End Date
May 2018
Last Updated
9 years ago
Study Type
Expanded Access
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •ECOG Performance Status of 0-1
  • •Histologically confirmed malignant melanoma
  • •Progressed on or after treatment with an anti-CTLA4

Exclusion Criteria

  • •Active brain metastases
  • •Life Expectancy \<6 weeks
  • •Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy
  • •Subjects with autoimmune disease

Outcomes

Primary Outcomes

Not specified

Study Sites (21)

Loading locations...

Similar Trials

No Longer Available
Not Applicable
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenSquamous Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung Cancer
NCT02475382Bristol-Myers Squibb
No Longer Available
Not Applicable
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaMalignant Melanoma
NCT02186249Bristol-Myers Squibb
Not yet recruiting
Not Applicable
EXPANDED ACCESS PROGRAM WITH NIVOLUMAB FOR SUBJECTS WITH HISTOLOGICALLY CONFIRMED STAGE III (UNRESECTABLE) OR STAGE IV MELANOMA PROGRESSING POST PRIOR SYSTEMIC TREATMENT CONTAINING AN ANT-CTLA-4 MONOCLONAL ANTIBODY.-C439 Malignant melanoma of skin, unspecifiedMalignant melanoma of skin, unspecifiedC439
PER-012-15BRISTOL MYERS SQUIBB COMPANY,
No Longer Available
Not Applicable
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)Extranodal NK/T-cell Lymphoma
NCT05131438EQRx International, Inc.
Recruiting
Not Applicable
Expanded Access Program with Nivolumab (ONO-4538) for malignant non-pleural mesothelioma (VIOLA)Malignant MesotheliomaNivolumabMesothelioma
JPRN-jRCT2051220186Kijima Takashi15